Melissa S. Barnes net worth and biography

Melissa Barnes Biography and Net Worth

Melissa Stapleton Barnes serves as Independent Director of the Company. Ms. Melissa Barnes has been Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer for Eli Lilly and Company (“Lilly”) since 2013. Ms. Barnes is an executive officer and a member of Lilly’s executive committee, reporting directly to the CEO and board of directors. Previous roles include Vice President and Deputy General Counsel from 2012 to 2013; and General Counsel, Lilly Diabetes and Lilly Oncology from 2010 to 2012. Ms. Barnes holds a Bachelor of Science in Political Science and Government (with highest distinction) from Purdue University and a Juris Doctorate from Harvard Law School. Ms. Barnes chairs the Ethics and Business Integrity Committee for the International Federation of Pharmaceutical Manufacturers and Associations; serves as an executive advisor for Ethisphere’s Business Ethics Leadership Alliance; is a Fellow with the Ethics and Compliance Initiative; and is a Licensed Attorney with the Indiana State Bar. Ms. Barnes’ other board positions include The Center for the Performing Arts (Chair), The Great American Songbook Foundation (Immediate Past Chair), Timmy Global Health, and the Ethics Research Council.

What is Melissa S. Barnes' net worth?: The estimated net worth of Melissa S. Barnes is at least $18.03 million as of September 8th, 2020. Ms. Barnes owns 23,580 shares of Eli Lilly and Company stock worth more than $18,031,862 as of December 18th. This net worth estimate does not reflect any other assets that Ms. Barnes may own. Learn More about Melissa S. Barnes' net worth.
How do I contact Melissa S. Barnes?: The corporate mailing address for Ms. Barnes and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Melissa S. Barnes' contact information.
Has Melissa S. Barnes been buying or selling shares of Eli Lilly and Company?: Melissa S. Barnes has not been actively trading shares of Eli Lilly and Company during the past quarter. Most recently, Melissa S. Barnes sold 5,000 shares of the business's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $151.01, for a transaction totalling $755,050.00. Following the completion of the sale, the senior vice president now directly owns 23,580 shares of the company's stock, valued at $3,560,815.80. Learn More on Melissa S. Barnes' trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 11/8/2024.

Melissa S. Barnes Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/8/2020	Sell	5,000	$151.01	$755,050.00	23,580
4/12/2019	Sell	4,735	$125.15	$592,585.25	22,085
6/12/2017	Sell	1,900	$80.78	$153,482.00	14,041
12/16/2016	Sell	2,093	$82.23	$172,107.39	8,169
6/10/2016	Sell	992	$73.77	$73,179.84	10,710

Melissa S. Barnes Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $764.71

$762.50

$779.00

50 Day Range

MA: $828.39

$727.57

$932.06

2 Week Range

Now: $764.71

$567.02

$972.53

Volume

3,303,963 shs

Average Volume

3,209,608 shs

Market Capitalization

$725.95 billion

P/E Ratio

82.67

Dividend Yield

0.66%

Beta

0.41

Uncover the Top Gold Stock of the Bull Market

From Huge Alerts | Ad

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.